101641-9 |
Myeloid sarcoma analysis |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
Myeloid sarcoma analysis in Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
101641-9 |
|
FISH |
|
|
Both |
|
|
|
0 |
Myeloid sarcoma analysis Bld/T FISH |
|
|
|
N |
|
Blood; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Myelo; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101642-7 |
Cardiovascular risk panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Cardiovascular risk panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
101642-7 |
|
|
|
|
Order |
|
|
|
0 |
Cardiovascular risk pnl SerPl |
|
|
|
N |
|
Molecular pathology; MOLPATH; Pan; Panel.molpath; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101643-5 |
Cells.CD3^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
NCnc |
Bld |
Pt |
Qn |
|
|
TRIAL |
CD3 cells [#/volume] in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
|
ADD |
DefinitionDescription |
|
|
cells/uL |
|
|
|
|
|
|
MICRO |
|
101643-5 |
|
|
|
|
Both |
|
|
|
0 |
CD3 Cells p COVID NuclCap # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Blood; CD3 Cells; Cell; Cells.CD3 p COVID NuclCap; Cellularity; Cnt; Count; Count/volume; CT; II; Leu4; Leu-4; Microbiology; Number concentration; Number Concentration (count/vol); p COVID NuclCap; Pept; Point in time; QNT; Quan; Quant; Quantitative; Random; Severe Acute Respiratory Syndrome; Stim; T3; WB; Whole blood |
2.75 |
2.75 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
101644-3 |
Cells.CD3+CD4+^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD3+CD4+ (T4 helper) cells [#/volume] in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
|
ADD |
DefinitionDescription |
|
|
cells/uL |
|
|
|
|
|
|
MICRO |
|
101644-3 |
|
|
|
|
Both |
|
|
|
0 |
CD3+CD4+ Cells p COVID NuclCap # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Blood; CD3 Cells; CD3+CD4+ Cells; CD3-CD4+; CD4+ T cells; Cell; Cells.CD3+CD4 + p COVID NuclCap; Cellularity; Cnt; Count; Count/volume; CT; Helper T cells; II; Inducer T cells; L3T4; Leu3; Leu-3; Leu4; Leu-4; Microbiology; Number concentration; Number Concentration (count/vol); p COVID NuclCap; Pept; Point in time; QNT; Quan; Quant; Quantitative; Random; Severe Acute Respiratory Syndrome; Stim; T3; T4; T-4; T4 helper/inducer cells; W3/25; WB; Whole blood |
2.75 |
2.75 |
|
|
|
|
|
|
|
{cells}/uL |
|
|
|
0 |
101645-0 |
Cells.CD3+CD8+^after stimulation with Sars-CoV-2 nucleocapsid peptide |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
|
ADD |
DefinitionDescription |
|
|
cells/uL |
|
|
|
|
|
|
MICRO |
|
101645-0 |
|
|
|
|
Both |
|
|
|
0 |
CD3+CD8+ Cells p COVID NuclCap # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Blood; CD3 Cells; CD3+CD8+ Cells; CD8 T cells; Cell; Cells.CD3+CD8+ p COVID NuclCap; Cellularity; Cnt; Count; Count/volume; CT; II; Leu2; Leu-2; Leu4; Leu-4; Microbiology; Number concentration; Number Concentration (count/vol); p COVID NuclCap; Pept; Point in time; QNT; Quan; Quant; Quantitative; Random; Severe Acute Respiratory Syndrome; Stim; Suppressor T cells; Suppressor/cytotoxic T cells; T3; T8; T-8; T8 suppressor cells; Tsuppressor; WB; Whole blood |
2.75 |
2.75 |
|
|
|
|
|
|
|
{cells}/uL |
|
|
|
0 |
101646-8 |
Candida albicans+dubliniensis+parapsilosis+tropicalis DNA |
PrThr |
Vag |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis DNA [Presence] in Vaginal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101646-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Candida sp group DNA Vag Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C albicans; Cand; Candida sp group; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m005; m5; Microbiology; Monilia; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; Thrush; TMA; Transcription mediated amplification; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101647-6 |
Ehrlichiosis & Anaplasmosis & Babesiosis & Borrelia miyamotoi DNA panel |
- |
Ser/Plas/Bld |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Ehrlichiosis and Anaplasmosis and Babesiosis and Borrelia miyamotoi DNA panel - Serum, Plasma or Blood by NAA with probe detection |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101647-6 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
Tick Pnl SerPlBld NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B miyamotoi; B miyamotoi DNA; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pl; PlasBld; Plasma; Plsm; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; Strand Displacement Amplification; TBRF; Tick Borne Diseases; Tick Pnl; tick-borne relapsing fever; TMA; Transcription mediated amplification; WB; Whole blood |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101648-4 |
14-3-3 Ag |
MCnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
14-3-3 Ag [Mass/volume] in Cerebral spinal fluid by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHEM |
|
101648-4 |
|
IA |
|
|
Both |
|
|
|
0 |
14-3-3 Ag CSF IA-mCnc |
|
|
|
N |
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; CJ; CJD; Creutzfeldt-Jacob Disease; Creutzfeldt-Jakob Disease; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; III; Level; Mass concentration; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
101649-2 |
Tau protein |
MCnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
Tau protein [Mass/volume] in Cerebral spinal fluid by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
101649-2 |
|
IA |
|
|
Both |
|
|
|
0 |
Tau Prot CSF IA-mCnc |
|
|
|
N |
|
Alzheimer disease; Alzheimer's disease; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Level; Mass concentration; MEIA; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.75 |
2.75 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
10165-9 |
History of psychiatric symptoms & diseases |
Find |
^Patient |
Pt |
Nar |
Reported |
|
DEPRECATED |
Deprecated History of psychiatric symptoms and diseases Narrative |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10165-9 |
|
Reported |
|
|
|
|
|
|
0 |
Deprecated Psych symptoms & diseases Hx |
|
|
|
|
|
Finding; Findings; H/O; H+P; H+P.HX; Hx; Narrative; P prime; Point in time; Psych symptoms & diseases Hx; Random; Report; Sx; Symp + dis |
2.4 |
1.0i |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
101650-0 |
Prion disease risk |
Imp |
CSF |
Pt |
Nar |
IA |
|
ACTIVE |
Prion disease risk [Interpretation] in Cerebral spinal fluid by Immunoassay Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
101650-0 |
|
IA |
|
|
Both |
|
|
|
0 |
Prion disease risk CSF IA-Imp |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Dis; Diseases; Dz; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; MEIA; Narrative; Point in time; Random; Report; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101651-8 |
MYC and BCL2 rearrangements |
Find |
Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
MYC and BCL2 rearrangements in Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
101651-8 |
|
FISH |
|
|
Observation |
|
|
|
0 |
BLYM Tiss FISH |
|
|
|
N |
|
B-cell leukemia/lymphoma 2; BCL-2; BLYM; Burkitt lymphoma; Burkitts lymphoma; c-MYC; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Point in time; Protooncogene homologous to myelocytomatosis virus; Random; Rearr; Rearrangement; Tissue; Tissue, unspecified; v-myc myelocytomatosis viral oncogene homolog |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101652-6 |
Somatotropin & glucose post glucose stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Somatotropin and glucose post glucose stimulation panel - Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101652-6 |
|
|
|
|
Order |
|
|
|
0 |
GH + Glc pst Glc stim pnl SerPl |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; GH; GH + Glc pst Glc stim pnl; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; Growth hormone; GTT; HGH; Human growth hormone; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Stim |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101653-4 |
Prenatal hepatitis B & C panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Prenatal hepatitis B and C panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101653-4 |
|
|
|
|
Order |
|
|
|
0 |
PHSP SerPl |
|
|
|
N |
|
Hep; Hepatis; Hepatit; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; PHSP; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101654-2 |
Neonatal ABO, Rh & DAT panel |
- |
Bld^Newborn |
Pt |
- |
|
|
ACTIVE |
Neonatal ABO, Rh and DAT panel - Blood from Newborn |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.BLDBK |
|
101654-2 |
|
|
|
|
Order |
|
|
|
0 |
NEVAL Bld NB |
|
|
|
N |
|
Blood; BLOOD BANK; D phenotyping; D typing; NB; NEVAL; New born; Pan; PANEL.BLOODBANK; Panl; Pnl; Point in time; Random; Rh phenotyping; Rh typing; WB; Whole blood |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101655-9 |
Basic metabolic & hematocrit panel |
- |
Bld |
Pt |
- |
|
|
ACTIVE |
Basic metabolic and hematocrit panel - Blood |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101655-9 |
|
|
|
|
Order |
|
|
|
0 |
Basic metabolic and hematocrit pnl Bld |
|
|
|
N |
|
Basic metabolic and hematocrit pnl; Blood; Chemistry; Hct; Pan; PANEL.CHEMISTRY; Panl; PCV; Pnl; Point in time; Random; WB; Whole blood |
2.77 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101656-7 |
Lactate & pyruvate panel |
- |
Ser/Plas/Bld |
Pt |
- |
|
|
ACTIVE |
Lactate and pyruvate panel - Serum, Plasma or Blood |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101656-7 |
|
|
|
|
Order |
|
|
|
0 |
Lactate & pyruvate pnl SerPlBld |
|
|
|
N |
|
2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Blood; Chemistry; Lact; Lactate & pyruvate pnl; Lactic acid; L-lactate; Pan; PANEL.CHEMISTRY; Panl; Pl; PlasBld; Plasma; Plsm; Pnl; Point in time; Pyruvic acid; Random; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101657-5 |
Special investigation unit (SIU) medical record request |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Special investigation unit (SIU) medical record request Document |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
101657-5 |
|
|
|
|
Both |
|
|
|
0 |
SIU medical record request Doc |
|
|
|
N |
|
DOC.MISC; Document; Finding; Findings; MISC; Point in time; Random; SIU medical record request |
2.75 |
2.75 |
Y |
|
|
|
|
|
|
|
|
|
|
0 |
101658-3 |
Cancer staging after multimodality therapy |
Find |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Cancer staging after multimodality therapy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ONCOLOGY |
|
101658-3 |
|
|
|
|
Both |
|
|
|
0 |
Ca staging aft multimodality thrpy |
|
|
|
N |
|
CA; Ca staging aft multimodality thrpy; Cancer; Finding; Findings; Misc; Miscellaneous; Nominal; ONCOLOGY; Other; Point in time; Random; Spec; TNM staging after multimodality therapy; To be specified in another part of the message; Unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101659-1 |
Cancer staging after tumor recurrence |
Find |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Cancer staging after tumor recurrence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ONCOLOGY |
|
101659-1 |
|
|
|
|
Both |
|
|
|
0 |
Cancer staging after tumor recurrence |
|
|
|
N |
|
CA; Cancer; Finding; Findings; Misc; Miscellaneous; Nominal; ONCOLOGY; Other; Point in time; Random; Spec; TNM staging after tumor recurrence; To be specified in another part of the message; Unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10166-7 |
Social function |
Hx |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
History of Social function Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10166-7 |
|
|
|
|
|
|
|
|
0 |
Hx of Social function |
|
|
|
|
|
FCN; Func; Funct; H+P; H+P.HX; History; Narrative; P prime; Point in time; Random; Report |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101660-9 |
Cancer staging during autopsy |
Find |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Cancer staging during autopsy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ONCOLOGY |
|
101660-9 |
|
|
|
|
Both |
|
|
|
0 |
Cancer staging during autopsy |
|
|
|
N |
|
CA; Cancer; Finding; Findings; Misc; Miscellaneous; Nominal; ONCOLOGY; Other; Point in time; Random; Spec; TNM staging during autopsy; To be specified in another part of the message; Unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101661-7 |
Tumor marker level |
Find |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Tumor marker level Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ONCOLOGY |
|
101661-7 |
|
|
|
|
Both |
|
|
|
0 |
Tumor marker level Ser |
|
|
|
N |
|
Cancer; Finding; Findings; Levels; Levl; LV; LVL; Mark; Nominal; ONCOLOGY; Point in time; Random; Serum; SR |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101662-5 |
Prion protein.abnormal |
PrThr |
CSF |
Pt |
Ord |
RT-QuIC |
|
ACTIVE |
Abnormal Prion Protein [Presence] in Cerebral spinal fluid by RT-QuIC |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
101662-5 |
|
RT-QuIC |
|
|
Both |
|
|
|
0 |
Abn Prion Prot CSF Ql RT-QuIC |
|
|
|
N |
|
abn; Abn Prion Prot; abnorm; Bovine spongiform encephalopathy; BSE; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Ordinal; Point in time; PR; Prot; PrP; QL; Qual; Qualitative; Random; Scrapie; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101663-3 |
T-Cell acute lymphoblastic leukemia |
Find |
Bld/Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
T-Cell acute lymphoblastic leukemia in Blood or Tissue by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
101663-3 |
|
FISH |
|
|
Both |
|
|
|
0 |
TALAF Bld/T FISH |
|
|
|
N |
|
Blood; Document; Finding; Findings; Fluorescent in situ hybridization; Molecular pathology; MOLPATH; Point in time; Random; T cell; T prime; TALAF; TALMF; TALPF; Tissue; Tissue, unspecified; UCHL-1; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |